Freakonomics Radio 659. Can Marty Makary Fix the F.D.A.?
387 snips
Jan 16, 2026 
Marty Makary, a prominent physician-scientist and FDA Commissioner, passionately discusses pivotal healthcare reforms. He critiques historical FDA failures, like OxyContin's approval, and the impact of outdated medical dogmas on allergies and dietary advice. Makary emphasizes his agenda for faster drug approvals and price transparency, while tackling misleading prescription ads. He also highlights innovative approaches using AI and organ-on-chip technology for drug testing. Listeners gain insight into his bold vision to cure diabetes and improve public health.
AI Snips
Chapters
Books
Transcript
Episode notes
Promising Stories In Cures Pipeline
- Makary cites pancreas beta-cell lab growth and a baby's gene therapy as promising examples.
- He says the FDA will proactively engage early to help accelerate such novel therapies.
Leucovorin Label Change For Autism
- The FDA announced adding cerebral folate deficiency and autism to leucovorin's label based on clinical and observational data.
- Makary says the drug is safe, generic, and may help a subset of children with autism.
Tylenol Link Is Mixed Evidence
- Studies linking prenatal acetaminophen to autism are mixed, with dozens supporting association and others not.
- Makary defended making the evidence available to clinicians while acknowledging uncertainty.
